title: Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
abstract: We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.
authors: Department of Pediatric Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. W.Leen@neuro.umcn.nl
authors: Wilhelmina G
authors: WG
authors: Leen
authors: Corry M
authors: CM
authors: Weemaes
authors: Marcel M
authors: MM
authors: Verbeek
authors: Michèl A
authors: MA
authors: Willemsen
authors: Jan J
authors: JJ
authors: Rotteveel
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007223:Infant; D053578:Opsoclonus-Myoclonus Syndrome / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab